Bevacizumab Toxicity in Glioblastoma
Pp. 46-50 (5)
Dawit Aregawi and David Schiff
Bevacizumab recently received approval from the United States Food and Drug Administration for use in recurrent glioblastoma. Although, most patients tolerate bevacizumab with tolerable side effects, occasional patients sustain life-threatening complications and many others require medical management in order to continue on the drug. This chapter reviews the spectrum of bevacizumab complications in patients with malignant glioma, including mechanism when known as well as management.
University of Michigan, Hematology/Oncology, C369 Med Inn Building, 1500 E Medical Center Dr., SPC 5848, Ann Arbor, MI 48109-5848.